Allakos (STU:37Z) Marketable Securities : €28.69 Mil (As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Allakos Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Allakos's Marketable Securities for the quarter that ended in Mar. 2025 was €28.69 Mil.

Allakos's annual Marketable Securities declined from Dec. 2022 (€181.79 Mil) to Dec. 2023 (€95.69 Mil) and declined from Dec. 2023 (€95.69 Mil) to Dec. 2024 (€60.23 Mil).

Allakos Marketable Securities Historical Data

The historical data trend for Allakos's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allakos Marketable Securities Chart

Allakos Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Marketable Securities

Get a 7-Day Free Trial

371.40

240.20

181.79

95.69

60.23

Allakos Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Marketable Securities	Get a 7-Day Free Trial															88.50	89.77	74.12	60.23	28.69

Allakos Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Allakos (STU:37Z) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Allakos Marketable Securities Related Terms

Thank you for viewing the detailed overview of Allakos's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Allakos Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allakos Inc (STU:37Z) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

ALLK:USA

Address

825 Industrial Road, Suite 500, San Carlos, CA, USA, 94070

Website

https://www.allakos.com

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation. Its portfolio consists of antibodies that target receptors, particularly Siglec-6, Siglec-8 and other anti-Siglec antibodies, including some antibodies in preclinical development.

Allakos Headlines

No Headlines